Aliskiren, the future of renin-angiotensin system blockade?

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 5, 2007, Pages 835-849

  Uresin, Yagiz ^a   Bozkurt, Manal Mehtar ^a   Sabirli, S ^a   Ozunal, Z G ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Aangiotensin converting enzyme inhibitors; Aliskiren; Angiotensin receptor blockers; Hypertension; Oral renin inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CELECOXIB; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; PRORENIN; RAMIPRIL; TEKTURNA; UNCLASSIFIED DRUG; VALSARTAN;

ALBUMINURIA; ANEURYSM RUPTURE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; CHEST TIGHTNESS; CLINICAL TRIAL; COLLAPSE; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PLASMA RENIN ACTIVITY; PROTEIN BLOOD LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG INTERACTIONS; FUMARATES; HUMANS; HYPERTENSION; KIDNEY; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34848880420     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.5.835     Document Type: Article

References (45)

1. Reid IA, The renin-angiotensin system, physiology, pathophysiology and pharmacology. Adv. Physiol. Educ. 275, 236-245 (1998).
2. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol. 1(2), 221-228 (2006).
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. 23(Suppl.), S9-S17 (2005).
4. Staessen Jan A, Li Y, Richart T. Oral renin inhibitors. Lancet 368(9545), 1449-1456 (2006)
5. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705 (2003).
6. Rigel DF, Fu F, Li S et al. The renin inhibitor aliskiren is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes. J. Am. Coll. Cardiol. 43(Suppl. A), 483A (2004).
7. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin activity inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576 (2005).
8. Fiebeler A, Shagdarsuren E, Pilz B et al. Low dose renin inhibitor and AT1 receptor blocker ameliorate angiotensin II-induced end-organ damage despite persistence of hypertension. Presented at Renal Week, PA, USA (2005).
9. Feldman DL, Jin L, Miserendino-Moltini R et al. The renin inhibitor aliskiren ameliorates hypertensive diabetic nephropathy in transgenic (mRen-2)27 (Ren-2) rats. Presented at Renal Week, PA, USA (2005).
10. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren, where are we now and where are we going? J. Hypertens. 24(2), 243-256 (2006).
11. Vaidyanathan S, Limoges D, Yeh C et al. PIII-23Aliskiren, an orally effective renin inhibitor, shows dose-linear pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 79(2), 64 (2006).
12. Nussberger J, Wuerzner G, Jensen C et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren, (SPP100), comparison with enalapril. Hypertension 39, E1-E8 (2002).
13. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Dieterich HA. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type 2 diabetes mellitus. Clin. Pharmacokinet. 45(11), 1125-1134 (2006).
14. Vaidyanathan S, Jin Y, Schiller H et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Clin. Pharmacol. Toxicol. 47, 192-200 (2007).
15. Vaidyanathan S, Valencia J, Kemp C et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. 60(11), 1343-1356 (2006).
16. Dieterle W, Corynen S, Vaidyanathan S et al. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharm. Ther. 43, 527-535 (2005).
17. Dieterich H, Kemp C, Vaidyanathan S et al. PIII-24Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin. Pharmacol. Ther. 79, 64 (2006).
18. Dieterich H, Kemp C, Vaidyanathan S et al. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers. Clin. Pharmacol. Ther. 79, 12 (2006).
19. Azizi M, Ménard J, Bissery A et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan an the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 15, 3126-3133 (2004).
20. Pool J, Gradman A, Kolloch R et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. World Congress of Cardiology, Barcelona, Spain (2000) (Abstract P790).
21. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25, 217-226 (2007).
22. Kilo C, Taylor A, Tschoepe D et al. Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasmarenin activity alone or in combination with ramipril in patients with diabetes. Eur. Heart J. 25(Suppl.), 118 (2006) (Abstract P789).
23. Sica D, Gradman A, Lederballe O et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur. Heart J. 25(Suppl.), 121 (2007) (Abstract P797).
24. Brookes L. New data on first-in-class oral renin inhibitor, aliskiren. Medscape conference coverage of the american society of hypertension 21st annual scientific meeting and exposition. NY. Medscape Cardiology, NY, USA (2006).
25. Munger MA, Drummond W, Essop MR et al. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur. Heart J. 25(Suppl.), 117. (Abstract P784) (2006).
26. Uresin Y, Taylor AA. Renin inhibitor aliskiren in combination with ACE inhibitor in diabetic patients with. hypertension. Presented at: The European Meeting on Hypertension. Madrid, Spain 12-16 June 2006.
27. Uresin Y, Taylor A, Kilo C et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J. Hypertens. 24(Suppl. 4), S82 (2006) (Abstract P4.269).
28. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49, 276-284 (2007).
29. Herron J, Mitchell J, Oh B et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J. Clin. Hypertens. 8(5 Suppl. A) A86-A87 (2006).
30. Kjeldsen SE. outcomes studies. In: European cardiovascular disease (Issue II). Touch Briefings, London, UK (2006).
31. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor aliskiren. Hypertension 42, 1137-1143 (2003).
32. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Cirrulation 111, 1012-1018 (2005).
33. Gradman AH, Schmieder RE, Lins RL, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Am. J. Hypertens. 17(5 Pt 2), 108A (2004).
34. Oh BH, Mitchell J, Herron JER, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 49, 1157-1163 (2007).
35. Oparil S, Yarows S, Patel S et al. The direct renin inhibitor aliskiren in combination with the angiotensin receptor blocker valsartan provides additional blood pressure-lowering effects compared with either agent alone in patients with hypertension. Poster presented at American College of Cardiology 2007 (2005).
36. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52, 11-34 (2000).
37. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369(9568), 1208-1219 (2007).
38. Alderman MH, Ooi WL, Cohen H et al. Plasma renin activity, a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. 10, 1-8 (1997).
39. Anan F, Takahashi N, Ooie T et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur. J. Clin. Pharmacol. 61, 353-359 (2005).
40. Micah L, Thorp DO. Diabetic nephropathy: common questions. MPH Lake road nephrology clinic Milwaukie, Oregon (2005).
41. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensinII production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
42. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 312, 1412-1417 (1985).
43. Davies L, Fulcher GR, Atkins A et al. The relationship of prorenin values to microvascular complications in patients with insulin dependent diabetes mellitus. J. Diabetes Complicat. 13, 45-51 (1999).
44. Chiarelli F, Pomilio M, De Luca FA, Vecchiet J, Verrotti A. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Int. J. Pediatr. Nephrol. 16(2), 116-120 (2001).
45. Kjeldsen SE. Direct renin inhibition with focus on aliskiren and cardiovascular outcome studies In: European Cardiovascular Disease (Issue II). Touch Briefings, London, UK (2006).